Skip to main content
Markets
/
EMCURE · NSE
Market closedNSE | BSE
Loading live market indices
EM
NSE · Equity shares · Biotechnology & Drugs

Emcure Pharmaceuticals EMCURE

NSE:INR 1,936.7Recorded price
BSE:INR 1,936.1Recorded price
Not available · Not available
Advanced chart
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceStale · last-known data
Company fundamentalsStale · last-known data
Research sections8 of 9 availableMissing source values remain unavailable, never zero-filled.
Snapshot

Price and key statistics

Reported and computed values remain separate; missing values are not converted to zero.

Previous closeData unavailable
Day rangeINR 1,911.15 — INR 1,968.9
52-week rangeINR 1,260.1 — INR 2,008
VolumeNot available
Market cap36,502.25
P/E32.71
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)9,203.54
Net Income (INR Cr)924.36
Rev Growth (5 Year %)8.73
EPS Growth (5 Year %)18.65
P/E Ratio32.71
Book Value203.01
EPS49.98
Price/BV9.54Computed

Research path: Interpret Emcure Pharmaceuticals's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.

AI and Advanced

AI analysis and Advanced tools for EMCURE

Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.

AI analysisReview the complete evidence-led AI research workflow.Generate reportCreate a versioned report with entitlement and credit checks.Open AI ChatContinue a grounded conversation with the instrument in context.Advanced modulesOpen role- and entitlement-controlled portfolio and trading tools.
Validated OHLC

Interactive price chart

Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.

Open full workspace
Interactive price chartInteractive chart loads when this section is visible.
Auditable calculations

Daily technical summary

Calculated from validated daily candles. Descriptive research only.

Calculating technicals…
Intelligence: activity, structure and reported deals

Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.

Company derivatives · NSE

EMCURE futures & options

Expiry structure, futures, option chains and contract research.

Snapshot · timestamp unavailable
No observations

No matching contracts have verified observations for this filter.

DIRECTION · ACTIVITY · DISCLOSURES

EMCURE Intelligence

Stored price, volume, causal structure and reported deals for this stock.

Market map
Checking research access…

Volume and pressure are activity estimates, not net money inflow. Futures and options retain their separate observations above.

Company reporting

Financial statements

IND AS · INR crore

Metric202620252024
Total Liabilities Shareholders' Equity9,612.488,232.727,806.16
Cash Equivalents147.5228.1260.61
Other Liabilities Total111.08355.61354.17
Long Term Debt252.21187.34761.92
Common Stock Total189.59189.48181.15
Other Current Assets Total435.315.949.65
Total Assets9,612.488,232.727,806.16
Current Portof LT Debt/Capital Leases1,006.75100.87390.66
Total Equity4,950.034,446.192,952.28
Long Term Investments60.9422.1319.99
Retained Earnings(Accumulated Deficit)4,760.443,388.592,712.52
Total Common Shares Outstanding18.9618.9518.91
Tangible Book Valueper Share Common Eq203.01184.67109.25
Goodwill Net414.26367.78378.69
Total Liabilities4,662.453,786.544,853.88
Total Debt1,521.241,022.752,334.97
Short Term Investments68.7485.13348.39
Cashand Short Term Investments216.26240.66517.39
Total Receivables Net2,562.662,288.132,113.34
Deferred Income Tax98120.03137.42
Accounts Receivable-Trade Net2,562.662,002.921,873.48
Property/Plant/Equipment Total-Net2,490.822,427.122,397.21
Minority Interest26.64195.37169.48
Total Current Liabilities3,912.242,668.273,210.47
Total Inventory2,397.871,931.811,525.1
Accounts Payable1,807.771,479.581,309.37
Other Currentliabilities Total1,097.73413.72355.41
Total Long Term Debt514.49447.25982.34
Intangibles Net686.84579.23507.77
Other Long Term Assets Total250.59156.52138.07
Note Receivable-Long Term96.93124.08104.53
Total Current Assets5,612.14,555.864,259.92
Capital Lease Obligations262.28259.92220.42
Accumulated Depreciation TotalNot available-1,533.89-1,307.58
Accrued ExpensesNot available199.48193.07
Other Equity TotalNot available82.8648.73
Prepaid ExpensesNot available89.3194.44
Additional Paid-In CapitalNot available785.259.88
CashNot available127.41108.4
Property/Plant/Equipment Total-GrossNot available3,836.953,572.45
Notes Payable/Short Term DebtNot available474.62961.98
Fundamentals

Valuation and ratios

Valuation

PEG Ratio2

Price to Sale Ratio3.97

Growth

Debt 5Yr CAGR %-9.16

Margins

Operating Margin 12m14.12

Operating Margin 5y Avg14.84

Net Profit Margin 12m10.23

Net Profit Margin 5y9.67

Yield

Dividend Yield %0.18

Risk and consensus

Source-qualified signals

Risk metrics

Overall RiskBalanced risk

Board Risk33.84

Analyst consensus

ConsensusStrong Buy

Consensus score1.33

Analyst opinions6

Strong Sell count0

Sell count0

Hold count1

Buy count0

Strong Buy count5

Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.
Industry context

Peer comparison

Only peers present in the company profile payload are displayed.

CompanyPriceMarket capP/EResearch
Sun Pharmaceutical IndustriesINR 1,9444.66 L38.4—
Divi's LaboratoriesINR 8,291.552.20 L73.32—
Torrent PharmaceuticalsINR 4,9651.89 L72.73—
CiplaINR 1,4751.19 L27.57—
Zydus LifesciencesINR 1,106.251.10 L21.19—
Shareholding

Ownership

Promoter
77.83%
FII
4.87%
MF
6.87%
Other
10.43%
Company intelligence

Latest relevant news

Source, timestamp and external destination are shown. Provider relevance scores are not available.

ICMR Licenses Three Indigenous Health Technologies to Indian Industry - DevdiscourseMarket news · 21 Jul 2026, 8:46 pm

ICMR Licenses Three Indigenous Health Technologies to Indian Industry Devdiscourse

ICMR transfers indigenous cervical cancer drug and vaccine technologies to Emcure and Biological E - BusinessLineMarket news · 21 Jul 2026, 8:17 pm

ICMR transfers indigenous cervical cancer drug and vaccine technologies to Emcure and Biological E BusinessLine

Emcure Pharmaceuticals Limited Announces Cessation of P.S. Jayakumar as Independent Director and from Board Committees, Effective July 21, 2026 - marketscreener.comMarket news · 21 Jul 2026, 5:21 pm

Emcure Pharmaceuticals Limited Announces Cessation of P.S. Jayakumar as Independent Director and from Board Committees, Effective July 21, 2026 marketscreener.com

Emcure Pharmaceuticals director P.S. Jayakumar ceases to be director - scanx.tradeMarket news · 21 Jul 2026, 4:25 pm

Emcure Pharmaceuticals director P.S. Jayakumar ceases to be director scanx.trade

Emcure Pharma up 3% after CDSCO approves semaglutide for MASH treatment - Business StandardMarket news · 21 Jul 2026, 2:28 pm

Emcure Pharma up 3% after CDSCO approves semaglutide for MASH treatment Business Standard

ICMR transfers three indigenous biomedical technologies - Pharmabiz.comMarket news · 21 Jul 2026, 2:16 pm

ICMR transfers three indigenous biomedical technologies Pharmabiz.com

Corporate actions

Events

  1. board MeetingsQuarterly Results
  2. dividendRs.3.6000 per share(36%)Final Dividend
  3. board MeetingsAudited Results & Final Dividend
  4. annual General MeetingPOM
  5. annual General MeetingPOM
  6. board MeetingsQuarterly Results
  7. board MeetingsQuarterly Results
  8. annual General MeetingAGM
  9. dividendRs.3.0000 per share(30%)Final Dividend
  10. board MeetingsQuarterly Results
  11. board MeetingsAudited Results & Final Dividend
  12. board MeetingsQuarterly Results
  13. annual General MeetingPOM
  14. board MeetingsQuarterly Results
  15. board MeetingsQuarterly Results
Rusaka Markets Community

Discussion and sentiment for Emcure Pharmaceuticals

Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.

Rusaka Markets Community

Community discussion loads as you approach this section.

Company profile

Business information

What the company does

Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and Active Pharmaceutical Ingredient (APIs). It operates across a wide scope of areas, including Gynecology, Cardiovascular, HIV Antivirals, VMN (Vitamins, Minerals & Nutrients), Pain/Analgesics, Nephrology, Oncology, Anti-Infective, Respiratory, CNS. Its brands include Orofer XT and Pause (Gynecological), Proxym (pain), Tenectase (CNS), Vylda (diabetology), Vitanova (VMN). Its API products include S-Amlodipine, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (Tenecteplase), Vintor (Erythropoietin), TENECTASE (Tenecteplase). It has developed two platforms: Mammalian and Microbial.

Company facts

Industry
Biotechnology & Drugs
Sector
Biotechnology & Drugs
NSE Code
EMCURE
BSE Code
544210
Questions

Stock FAQ

What is the symbol and ISIN of Emcure Pharmaceuticals?

Emcure Pharmaceuticals has the symbol EMCURE and ISIN - INE168P01015.

What is the latest recorded price of Emcure Pharmaceuticals?

The latest available recorded price of Emcure Pharmaceuticals is INR 1,936.70 as of 2026-08-06T20:49:46.775Z. This is a source-stamped snapshot, not a live quote.

What are the year high and year low of Emcure Pharmaceuticals?

Year high: INR 2,008.00. Year low: INR 1,260.10.

What is the market capitalization of Emcure Pharmaceuticals?

Market capitalization: INR 36,502.25 crore.

What is the P/E ratio of Emcure Pharmaceuticals?

P/E ratio: 32.71.

What is the dividend yield of Emcure Pharmaceuticals?

Dividend yield: 0.18%.

How is the financial performance of Emcure Pharmaceuticals based on revenue, net income, and EPS?

Revenue: INR 9,203.54 crore. Net income: INR 924.36 crore. EPS: INR 50.00.

What is the book value of Emcure Pharmaceuticals?

Book value: INR 203.01.

What are the price-to-book and price-to-sales ratios of Emcure Pharmaceuticals?

Price-to-book ratio: 9.54. Price-to-sales ratio: 3.97.

Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.